Arcutis BiotherapeuticsARQT
ARQT
About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Employees: 342
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
107% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.96M
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
50% more capital invested
Capital invested by funds: $1.2B [Q3] → $1.79B (+$597M) [Q4]
11% more funds holding
Funds holding: 187 [Q3] → 207 (+20) [Q4]
0.17% more ownership
Funds ownership: 109.9% [Q3] → 110.07% (+0.17%) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 66
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
15%
upside
Avg. target
$18.80
45%
upside
High target
$21
61%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Needham Serge Belanger 36% 1-year accuracy 44 / 123 met price target | 54%upside $20 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 29 / 171 met price target | 46%upside $19 | Buy Reiterated | 3 Apr 2025 |
Jefferies Kambiz Yazdi 25% 1-year accuracy 1 / 4 met price target | 46%upside $19 | Buy Maintained | 11 Mar 2025 |
Goldman Sachs Jonathan Block 0% 1-year accuracy 0 / 19 met price target | 15%upside $15 | Neutral Maintained | 27 Feb 2025 |
Mizuho Uy Ear 17% 1-year accuracy 1 / 6 met price target | 61%upside $21 | Outperform Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 9 articles about ARQT published over the past 30 days
Positive
Seeking Alpha
15 hours ago
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicaid coverage, bolstered by a robust sales force.
Neutral
GlobeNewsWire
2 days ago
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close.
Neutral
GlobeNewsWire
1 week ago
Arcutis Announces Chief Financial Officer Transition
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO until the filing of the Company's first quarter 10-Q and will provide transition support through his departure on May 15, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,000 restricted stock units of Arcutis' common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
2 weeks ago
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
GlobeNewsWire
2 weeks ago
Arcutis and Padagis Agree to Stay Patent Lawsuit
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the U.S. District Court for the District of Delaware on April 2, 2025. After the Court enters the joint stipulation, all calendared dates and trial for the patent litigation will be vacated.
Positive
Zacks Investment Research
3 weeks ago
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
3 weeks ago
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Negative
Benzinga
3 weeks ago
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Positive
Zacks Investment Research
1 month ago
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Charts implemented using Lightweight Charts™